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Thirty adult patients with non-Hodgkin’s lymphoma were studied to evaluate prospectively the signiﬁcance of early decline in
left ventricular ejection fraction after low cumulative doxorubicin dose (200 mg m
72) in predicting the later impairment of left
ventricular function. Cardiac function was monitored with radionuclide ventriculography at baseline and after cumulative
doxorubicin doses of 200, 400 and 500 mg m
72. Cardiotoxicity was deﬁned as a decrease in left ventricular ejection fraction
of more than 10% units to a ﬁnal left ventricular ejection fraction 450%. Twenty-eight patients received doxorubicin
5400 mg m
72 and were evaluable for cardiotoxicity. Clinical heart failure developed in two patients (7%) after a cumulative
doxorubicin dose of 500 mg m
72. Left ventricular ejection fraction decreased more than 10% absolute ejection fraction units
to a ﬁnal left ventricular ejection fraction 450% in 10 patients (36%). Left ventricular ejection fraction decreased from
56+1.5% to 53.6+1.5% (P=0.016) in patients with no cardiotoxicity, and from 60.8+2.4% to 41.8+2.0% (P50.001) in
patients with cardiotoxicity. For patients who developed cardiotoxicity, the fall in left ventricular ejection fraction after a
cumulative doxorubicin dose of only 200 mg m
72 was highly signiﬁcant (left ventricular ejection fraction 49.7+1.8%, P=0.001
vs baseline). In receiver operator characteristic analysis, the area under the curve for the decrease in left ventricular ejection
fraction at a cumulative doxorubicin dose of 200 mg m
72 for predicting cardiotoxicity in all patients was 0.858. The decrease
in left ventricular ejection fraction of more than 4% units after a cumulative doxorubicin dose of 200 mg m
72 had a 90%
sensitivity and 72% speciﬁcity for predicting later cardiotoxicity. Our results show that the signiﬁcant impairment of left
ventricular function during doxorubicin therapy can be predicted early, already at low cumulative doxorubicin doses. This
ﬁnding may be of value in identifying patients at high or low risk for the development of anthracycline cardiotoxicity.
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Doxorubicin is one of the most potent anti-neoplastic agents in the
treatment of lymphoid malignancies and many solid tumours.
However, its therapeutic value is limited by cumulative dose-
related cardiotoxicity. The incidence of congestive heart failure
(CHF) during doxorubicin treatment has been reported to be 3%
at a dose of 400 mg m
72 and 7% at a dose of 550 mg m
72
(von Hoff et al, 1979), but the occurrence of CHF is unpredictable.
Attempts to prevent CHF include empiric dose limitation and seri-
al assessment of left ventricular function. Only endomyocardial
biopsy has been considered to be sensitive and speciﬁc enough in
predicting the development of CHF (Mason et al, 1978; Billingham
and Bristow, 1984), but the invasiveness and potential complica-
tions of the procedure limit its clinical use. Radionuclide
ventriculography (RVG) has been regarded as the best noninvasive
method in identifying subclinical anthracycline cardiotoxicity in
adult patients (Alexander et al, 1979; Schwartz et al, 1987; Ganz
et al, 1996). Guidelines based on changes in systolic and diastolic
left ventricular function have been given for monitoring patients
receiving anthracycline therapy (Alexander et al, 1979; Schwartz
et al, 1987; Ganz et al, 1996).
Despite the introduction of new imaging techniques like
Indium-111-antimyosin (Carrio et al, 1995; Maini et al, 1997)
and Iodine-123-metaiodobenzylguanidine (MIBG) scans (Valde ￿s
Olmos et al, 1995; Carrio et al, 1995) and serum markers of left
ventricular dysfunction like natriuretic peptides (Bauch et al,
1992; Nousiainen et al, 1999; Meinardi et al, 2001) for the moni-
toring of cardiac function during anthracycline therapy, none of
these methods has been able to solve the problem of early detection
of severe anthracycline-induced cardiotoxicity.
In the present study we investigated the signiﬁcance of early
impairment of cardiac systolic function after low cumulative
doxorubicin dose (200 mg m
72) and its ability to predict the later
decrease in left ventricular ejection fraction (LVEF) during doxor-
ubicin therapy.
MATERIALS AND METHODS
Patients
Thirty consecutive adult patients 475 years of age with previously
untreated non-Hodgkin’s lymphoma, who were scheduled to
receive CHOP chemotherapy, were studied. The patients were
regarded as eligible for study entry if they had not received prior
anthracycline therapy or radiation therapy to mediastinum. A
history of heart failure was also considered as an exclusion criter-
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sive lymphoma and were not evaluable. Thus, the ﬁnal study
population consisted of 28 patients (17 men and 11 women) with
a mean age of 53 years (range 22–75 years). Six patients (21%)
were 565 years. Six patients (21%) had a pre-existing cardiovascu-
lar disease (four patients had WHO class II hypertension, one
patient had suffered from a prior myocardial infarction and one
patient from recurrent episodes of atrial ﬁbrillation). Of the
patients with a prior cardiovascular disease, two patients were over
65 years of age.
Approval for the study was obtained from the local ethical
committee and the patients provided written informed consent.
Chemotherapy
The CHOP chemotherapy was administered in standard doses
(cyclophosphamide, 750, doxorubicin, 50 and vincristine
1.4 mg m
72 were given intravenously on day 1 and prednisolone
100 mg orally on days 1–5). Doxorubicin was given as a 30 min
infusion. The cycle was repeated every 3 weeks to a total of 10
cycles. Doxorubicin was discontinued if left ventricular ejection
fraction (LVEF) decreased below 45% (Druck et al, 1984; Ganz
et al, 1996). No radiotherapy was given during the study period.
Radionuclide ventriculography
Radionuclide ventriculography (RVG) was performed at baseline
and after a cumulative doxorubicin dose of 200, 400 and
500 mg m
72. Left ventricular ejection fraction (LVEF) was assessed
using standard techniques (Wackers et al, 1979). The equilibrium
RVG was performed with semi in vitro technetium-99m-labelled
blood cells (injected activity 670 MBq). A large ﬁeld-of-view
gamma camera equipped with a high-sensitivity parallel hole colli-
mator was used for imaging. The cardiac cycle was divided into 24
frames with a 10% tolerance. Ten million counts were acquired.
Data were analysed with a commercial cardiac software (MGQ,
Nuclear Diagnostics Ab, Ha ¨gersten, Sweden). If the LVEF decreased
more than 10% units or was 550%, the RVG scan was repeated
before the subsequent CHOP course. A decrease of LVEF 410%
units to an ﬁnal LVEF 450% was used as a cut-off point in the
analyses as indicative of doxorubicin-induced cardiotoxicity (CT)
(Schwartz et al, 1987).
Statistical methods
All calculations were performed with SPSS/PC statistical program
(version 9.0, SPSS Inc., Chicago IL, USA). The differences for
continuous variables over time were analysed using general linear
model for repeated measures. Paired, two tailed t-tests were applied
for post-hoc analyses. Additional subgroup analyses for patients
with and without left ventricular dysfunction as deﬁned on the
basis of a decrease in LVEF were performed using Mann–Whitney
U-test for continuous variables and with Chi-Square test for
nominal data. Receiver operator characteristic analysis (ROC) was
used to evaluate the diagnostic ability of the decrease in LVEF after
a cumulative doxorubicin dose of 200 mg m
72 to predict the
development of doxorubicin-induced cardiotoxicity (CT). A P-
value 50.05 was considered as statistically signiﬁcant. The data
are expressed as mean+s.e.
RESULTS
Twenty-eight patients of the initial patient population received at
least eight courses of CHOP (cumulative doxorubicin dose
5400 mg m
72) and could be used in the analysis for evaluating
cardiotoxicity. Two patients died early because of progressive
lymphoma. Twenty-four patients received 10 cycles (cumulative
doxorubicin dose 500 mg m
72). The reason for discontinuation
or change of the treatment in four patients after eight cycles of
CHOP was suboptimal treatment response or disease progression.
The baseline LVEF of the patients was 58.0+1.3%. It decreased
to 52.5+1.1% (P50.001), 50.4+1.0% (P50.001) and 49.6+1.7%
(P50.001) after cumulative doxorubicin doses of 200, 400 and
500 mg m
72, respectively (Figure 1A). LVEF decreased more than
10% absolute EF units to a ﬁnal LVEF 450% in 10 patients
(36%). This cut-off point was reached after a cumulative dose of
200 mg m
72 in two patients, after 400 mg m
72 in four patients
and after 500 mg m
72 in four patients. Clinical heart failure devel-
oped in two patients (7%) at 1 month and 10 months after the last
dose of doxorubicin (cumulative dose 500 mg m
72). The patients
were a 43-year old previously healthy man and a 70-year-old man
with no history of heart disease or hypertension. These patients
presented with the decrease in LVEF of more of 10% units and
450% after a cumulative doxorubicin doses of 400 and
500 mg m
72, respectively.
Comparison of patients with and without cardiotoxicity
There were no differences in age, gender, hypertension, the use of
b-adrenoceptor blocking drugs, or LVEF between the patients with
or without CT, at baseline. In patients with no CT, LVEF decreased
from 56.4+1.5% to 54.0+1.3% (P=ns), 51.9+1.2% (P=0.029)
and to 53.6+1.5% (P=0.016), whereas in patients with CT, LVEF
decreased from 60.8+2.4% to 49.7+1.8% (P=0.001), 47.7+1.4%
(P50.001) and to 41.8+2.0% (P50.001) after cumulative doxor-
ubicin doses of 200, 400 and 500 mg m
72, respectively (Figure
1B). There was a statistically signiﬁcant difference in the decrease
in LVEF in patients with and without CT already after a cumula-
tive doxorubicin dose of 200 mg m
72 (711.1+2.3% units vs
72.4+1.2% units, P=0.001). The accuracy of the decrease in LVEF
after a cumulative doxorubicin dose of 200 mg m
72 to predict the
decrease in LVEF 410% units to the ﬁnal LVEF 450% in all
patients was estimated with ROC analysis. The area under the
curve was 0.858 (95% CI=0.713–1.004) (Figure 2). The decrease
in LVEF of more than 4% after a cumulative doxorubicin dose
of 200 mg m
72 units had a 90% sensitivity and 72% speciﬁcity
for predicting CT. This decrease in LVEF had a positive predictive
value of 64% and the negative predictive value of 93% for the
development of CT. Both patients with clinical CHF after doxoru-
bicin therapy had a decrease in LVEF of 8% units after a
cumulative doxorubicin dose of 200 mg m
72.
DISCUSSION
Early detection of subclinical anthracycline cardiotoxicity, and ulti-
mately the prevention of clinical congestive heart failure, is a
continuing challenge in clinical oncology. Attempts to minimise
cardiotoxicity include serial monitoring of cardiac function or
empiric anthracycline dose limitation. However, empiric limitation
or modiﬁcation of anthracycline dose, e.g. by risk factors, pose a
risk of premature discontinuation of effective anthracycline ther-
apy. On the other hand, because of a wide individual variability
in toxic anthracycline doses (von Hoff et al, 1979; Schwartz et al,
1987), cardiotoxicity may occur at unexpectedly low cumulative
doses. Serial assessment of LVEF by RVG has been the most
commonly used method of cardiac monitoring. According to the
guidelines proposed by Schwartz et al (1987), doxorubicin therapy
should be discontinued, if LVEF decreases 410% units to a ﬁnal
LVEF 450%. A baseline study should be performed before the
administration of cumulative doxorubicin dose of 100 mg m
72,
the next LVEF measurement should be performed at 250–
300 mg m
72 and again after 450 mg m
72 (after 400 mg m
72,i f
there are risk factors) and then after every treatment course
(Schwartz et al, 1987). However, low dose cardiotoxicity can occur
especially in patients with pre-existing risk factors and predispose
the patients to irreversible cardiac damage.
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British Journal of Cancer (2002) 86(11), 1697–1700 ã 2002 Cancer Research UKIn this prospective study, we evaluated the importance of low
doxorubicin dose cardiotoxicity and found that in patients, with
the ultimate cardiotoxic decrease in LVEF as proposed by
Schwartz et al (1987), the impairment of LVEF was statistically
signiﬁcant as early as after a cumulative doxorubicin dose of
200 mg m
72. Furthermore, we observed that the decrease in
LVEF of more than 4% units from the baseline after a cumulative
doxorubicin dose of 200 mg m
72 could in a speciﬁc and sensitive
manner predict the later decrease in LVEF. Thirty-six per cent of
our patients had a decrease in LVEF of more of 10% units and
450% after doxorubicin therapy. However, only two patients
developed manifest CHF after completion of therapy (cumulative
doxorubicin dose of 500 mg m
72). Both patients had a decrease
in LVEF of 8% units after a cumulative doxorubicin dose of
200 mg m
72.
In this study, the doxorubicin cardiotoxicity was deﬁned as a
decrease in LVEF (Schwartz et al, 1987) due to the small number
of patients studied and thus with low incidence of clinical CHF.
Although the guideline decrease in LVEF as proposed by Schwartz
et al (1987) is based on retrospective analysis, the risk of CHF was
reduced by four-fold when the guidelines were followed in their
study. Only two out of 70 patients (3%) in the cohort whose
management was concordant with the guidelines developed mild
CHF (Schwartz et al, 1987). Our observation of the value of the
early decrease in LVEF after a cumulative doxorubicin dose of
200 mg m
72 in predicting this guideline decrease in LV is intri-
guing and may allow the identiﬁcation of high risk patients, who
might need a more careful monitoring earlier in their treatment
course. On the other hand, the high negative predictive value of
93% of the early decrease in LVEF for the later impairment of
LV function seems to identify the patients with better tolerance
to higher cumulative anthracycline doses and hence less need for
cardiac monitoring. However, it must be born in mind that the
small number of the patients in our study might have had impact
on the results of ROC-analysis. Furthermore, these results are preli-
minary and need to be conﬁrmed in larger prospective studies
using clinically conﬁrmed CHF as an endpoint.
In order to prevent anthracycline cardiotoxicity, attempts have
focused on the development of safer anthracycline derivates like
liposomal doxorubicin (Alberts and Garcia, 1997) or molecules
with cardioprotective effects (Swain, 1998). On the other hand,
new sophisticated methods have been investigated for early detec-
tion and prevention of anthracycline-induced cardiotoxicity.
Indium-111-antimyosin scintigraphy has proven out to be a sensi-
tive indicator of myocardial cell injury including anthracycline
toxicity (Carrio et al, 1995; Maini et al, 1997). However, the anti-
body is not commercially available at the moment. Iodine-123-
metaiodobenzylguanidine (MIBG) is a norepinephrine analogue
which is taken up by myocardial sympathetic nerve endings and
reﬂects myocardial adrenergic integrity or function (Wieland et
al, 1981; Sisson et al, 1987). Decreased cardiac MIBG uptake has
been reported in some studies to precede the decrease in LVEF
in patients treated with doxorubicin (Valde ￿s Olmos et al, 1995;
Carrio et al, 1995). However, MIBG scintigraphy is available only
in few centers and the method cannot be regarded as a standard
method of follow-up of anthracycline therapy.
Plasma natriuretic peptides are biochemical markers of left
ventricular dysfunction. Atrial natriuretic peptide (ANP) and brain
natriuretic peptide (BNP) are synthesised, stored and secreted from
the heart in response to atrial or ventricular overload (Ruskoaho,
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Figure 1 Changes in left ventricular ejection (LVEF) during doxorubicin therapy. (A) represents data of all patients, and (B) represents data without and
with the decrease in LVEF 510% units to the ﬁnal LVEF 450%. *P50.05, ** P50.01, ***P50.001 vs baseline.
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Figure 2 ROC plot of the sensitivity and speciﬁcity of the decrease in left
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450% during doxorubicin therapy. The arrow indicates the decrease in
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peptides have been reported in patients treated with anthracyclines
(Bauch et al, 1992; Nousiainen et al, 1999; Meinardi et al, 2001).
Furthermore, it has been suggested that the measurement of plas-
ma natriuretic peptides could be used as an early indicator of
anthracycline cardiotoxicity (Bauch et al, 1992; Meinardi et al,
2001). However, we have previously shown that the increased
secretion of natriuretic peptides during doxorubicin therapy is a
compensatory phenomenon, not preceding but following the
decrease in LVEF (Nousiainen et al, 1999).
Thus, optimising the anthracycline dose and minimising the risk
of CHF; a dilemma in 1987 (Schwartz et al, 1987) is still a dilemma
today. In spite of the various methods for monitoring anthracycline
cardiotoxicity, none of the non-invasive methods have proven out
to be sensitive and speciﬁc enough to predict the development of
cardiomyopathy. Furthermore, despite the use of cardioprotectors
and new anthracycline derivates like liposomal doxorubicin, moni-
toring of cardiac function is still needed in clinical practice. In this
study, we observed that a signiﬁcant decrease in LVEF during
doxorubicin treatment can be observed, and later deterioration of
LV function predicted early, at a very low cumulative doxorubicin
dose.
Although our ﬁndings are preliminary, they may offer a more
rational and individualised basis for cardiac follow-up of
patients receiving anthracycline-based chemotherapy. In particu-
lar, patients with known risk factors for anthracycline-induced
cardiotoxicity, like older age, pre-existing cardiovascular disease
or history of mediastinal radiotherapy might be candidates for
this early monitoring, which quite accurately predicted the
future impairment of left ventricular function in this study.
On the other hand, patients with no signiﬁcant decrease in
LVEF at a cumulative doxorubicin dose of 200 mg m
72, seem
to have minor risk of cardiotoxicity and thus perhaps less need
for cardiac monitoring.
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